17 studies found for:    19097774 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Recruiting A Trial of TAS-114 in Combination With S-1
Condition: Advanced Solid Tumors
Interventions: Drug: TAS-114;   Drug: S-1
2 Recruiting An Investigation of TAS-119 Monotherapy and in Combination With Docetaxel
Condition: Advanced Solid Tumors
Interventions: Drug: Docetaxel;   Drug: TAS-119
3 Not yet recruiting A Study of Coti-2 for the Treatment of Advanced or Recurrent Gynecologic Malignancies
Conditions: Ovarian Cancer;   Fallopian Tube Cancer;   Endometrial Cancer;   Cervical Cancer;   Primary Peritoneal Cancer
Intervention: Drug: COTI2
4 Recruiting Intercalating and Maintenance Gefitinib in Combination With Chemotherapy for Advanced EGFR-mutant NSCLC
Conditions: Non-small Cell Lung Cancer Metastatic;   EGFR Activating Mutation
Interventions: Drug: Gefitinib;   Drug: gemcitabine;   Drug: carboplatin
5 Recruiting Study of Low-Dose Radiation Therapy to the Whole Liver in Combination With Gemcitabine and Cisplatin in Intrahepatic Cholangiocarcinoma
Condition: Intrahepatic Cholangiocarcinoma
Interventions: Drug: Gemcitabine;   Drug: Cisplatin;   Radiation: Low dose whole liver and portal lymph node basin radiotherapy
6 Recruiting Safety and Efficacy Study of Eribulin in Combination With Bevacizumab for Second-line Treatment HER2- MBC Patients
Conditions: Metastatic Breast Cancer;   Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
Intervention: Drug: Bevacizumab and eribulin
7 Withdrawn Tolfenamic Acid, Gemcitabine and Radiation for Locally Advanced or Metastatic Pancreatic Cancer Requiring Radiation
Condition: Pancreatic Cancer
Intervention: Drug: Tolfenamic acid + gemcitabine + radiation
8 Active, not recruiting Theranostic Tool During Erlotinib Treatment in Non-small Cell Lung Cancer Patient
Conditions: Non-small Cell Lung Cancer Metastatic or Non-small Cell Lung Cancer Recurrent;   No EGFR Activating Mutation
Interventions: Radiation: 18F-FLT-TEP;   Radiation: 18F-FDG-TEP
9 Recruiting Induction Gemcitabine and Cisplatin in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma
Condition: Nasopharyngeal Carcinoma
Interventions: Drug: gemcitabine and cisplatin (Induction chemotherapy);   Radiation: IMRT and concurrent cisplatin
10 Recruiting Radiotherapy for Oligometastatic Prostate Cancer
Condition: Oligometastatic Prostate Cancer
Intervention: Radiation: SBRT/SHRT
11 Recruiting Study Comparing Pathological Responses Observed on Colorectal Cancer Metastases Resected After Preoperative Treatment Combining Cetuximab With FOLFOX or FOLFIRI in RAS and B-RAF WT Tumors
Condition: Metastatic Colorectal Cancer
Interventions: Procedure: Metastases Resection ( multiple steep surgery possible);   Drug: 5-Fluorouracile;   Drug: leucovorin L;   Drug: Oxaliplatin;   Drug: Irinotecan;   Drug: Cetuximab
12 Recruiting Study Comparing Pathological Responses Observed on Colorectal Cancer Metastases Resected After Preoperative Bevacizumab With FOLFOX or FOLFIRI.
Condition: Metastatic Colorectal Cancer
Interventions: Procedure: Metastases resection;   Drug: Bevacizumab;   Drug: 5 FU;   Drug: Oxaliplatin;   Drug: Irinotecan
13 Recruiting European Low and Intermediate Risk Neuroblastoma Protocol
Condition: LOW AND INTERMEDIATE PAEDIATRIC NEUROBLASTOMA AND NEONATAL SUPRARENAL MASSES
Intervention: Drug: chemotherapy
14 Recruiting Ipilimumab and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Melanoma With Brain Metastases
Conditions: Recurrent Melanoma;   Stage IV Melanoma;   Tumors Metastatic to Brain
Interventions: Drug: Ipilimumab;   Radiation: Whole-Brain Radiation Therapy (WBRT);   Radiation: Stereotactic Radiosurgery (SRS)
15 Active, not recruiting Induction Chemotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma
Condition: Nasopharyngeal Carcinoma
Interventions: Drug: Docetaxel, cisplatin and fluorouracil;   Radiation: Concurrent chemoradiotherapy
16 Completed
Has Results
A Phase I/II Study of TRC105 in Metastatic Castrate Resistant Prostate Cancer (CRPC)
Conditions: Prostate Cancer;   Metastatic Castrate Resistant Prostate Cancer
Intervention: Drug: TRC105
17 Completed A Safety and Efficacy Study of KX2-391 in Patients With Bone-Metastatic, Castration-Resistant Prostate Cancer Who Have Not Received Prior Chemotherapy
Condition: Bone-Metastatic, Castration-Resistant Prostate Cancer
Intervention: Drug: KX2-391

Indicates status has not been verified in more than two years